Search Results - "Munoz, F. Longo"

Does Rapid Drug Desensitization to chemotherapy affect survival outcomes? by Berges-Gimeno, M P, Carpio-Escalona, L V, Longo-Muñoz, F, Bernal-Rubio, L, Lopez-Gonzalez, P, Gehlhaar, P, Pachon, V, Ferreiro-Monteagudo, R, Madrigal-Burgaleta, R, Alvarez-Cuesta, E

“…Oxaliplatin hypersensitivity reactions may affect prognosis by jeopardizing the timely completion of the scheduled treatment sessions, or by forcing reactive…”
Get full text

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial by Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero, R.

“…Purpose TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety…”
Get full text

P-016Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer by Longo Munoz, F, Earl, J, Martinez Avila, J, Rodriguez Garrote, M, Guerrero, C, Galindo, J, Priego, P, Rodriguez, G, Garcia-Moreno, F, Lopez, F, Hervas, A, Caminoa, A, Garcia, I, Soteras, C, Vazquez-Sequeiros, E, Botella, J, Pachon Olmos, V, Ferreiro Monteagudo, R, Vaz, M, Gomez, A, Guillen-Ponce, C, Carrato, A

Get full text

Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid by Martín Huertas, R., Longo Muñoz, F., Serrano Domingo, J., Corral de la Fuente, E., Pachón Olmos, V., Rodriguez Garrote, M., Fuentes, R., Ferreiro Monteagudo, R., Vaz, M., Carrato, A.

Get full text

FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group) by Longo Muñoz, F., Castillo Trujillo, O., Serrano Domingo, J., Martín Huertas, R., Corral de la Fuente, E., San Juan, A., Portela, J., Cano, J., Reguera Puertas, P., Rodriguez Garrote, M., Izquierdo Manuel, M., Jimenez Fonseca, P., Carrato, A., Aranda, E.

Get full text

Second line in pancreatic cancer: Resuming our experience and looking for prognostic factors by Anton, B., Muñoz, F. Longo, Abad, D. Gutierrez, De Torres Olombrada, M., Martel, I. Juez, Vila, B. Losada, Letéllez, J., Martínez, J. Guerra, Román, A. Fernñandez

Get full text

Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC) by Serrano Domingo, J., Martín Huertas, R., Corral de la Fuente, E., Barquín García, A., Saavedra Serrano, C., Albarrán Artahona, V., Reguera Puertas, P., Fuentes, R., Ferreiro Monteagudo, R., Olmos, V. Pachón, Vaz, M., Villamayor Delgado, M., Rodriguez Garrote, M., Carrato, A., Longo Muñoz, F.

Get full text

Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program by Moehler, M., Maderer, A., Thuss-Patience, P., Brenner, B., Hecker, J., Muñoz, F. Longo, Meiler, J., Ettrich, T., Hofheinz, R., Al-Batran, S., Vogel, A., Mueller, L., Lutz, M., Borchert, K., Greil, R., Alsina, M., Karatas, A., Van Cutsem, E., Keller, R., Larcher-Senn, J., Lorenzen, S.

Get full text

Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital by Serrano, C. Saavedra, Delgado, M. Villamayor, de la Fuente, E. Corral, García, A. Barquín, Domingo, J. Serrano, Huertas, R. Martín, Saez, O. Martínez, Muñoz, F. Longo, Puertas, P. Reguera, Olmos, V. Pachón, Garrote, M. Rodriguez, Vaz, M., Fuentes, R., Carrato, A., Monteagudo, R Ferreiro

Get full text

Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital by García, A. Barquín, Domingo, J. Serrano, Serrano, C. Saavedra, Artahona, V. Albarrán, Delgado, M. Villamayor, Saez, O. Martínez, Cerrillo, J. Molina, Huertas, R. Martín, de la Fuente, E. Corral, Monteagudo, R. Ferreiro, Garrote, M. Rodriguez, Olmos, V. Pachón, Vaz, M., Puertas, P. Reguera, Guillén-Ponce, C., Carrato, A., Muñoz, F. Longo

Get full text

Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant therapy in stage II in colon cancer: Experience in Ramon y Cajal Universitary Hospital by Huertas, R. Martín, Domingo, J. Serrano, de la Fuente, E. Corral, García, A. Barquín, Delgado, M. Villamayor, Serrano, C. Saavedra, Saez, O. Martínez, Muñoz, F. Longo, Olmos, V. Pachón, Garrote, M. Rodriguez, Vaz, M., Carrato, A., Puertas, P. Reguera, Fuentes, R., Monteagudo, R. Ferreiro

Get full text

Efficacy of adjuvant chemotherapy for elderly patients with colon cancer by Delgado, M. Villamayor, Serrano, C. Saavedra, de la Fuente, E. Corral, García, A. Barquín, Saez, O. Martínez, Huertas, R. Martín, Domingo, J. Serrano, Cerrillo, J. Molina, Muñoz, F. Longo, Olmos, V. Pachón, Garrote, M. Rodriguez, Puertas, P. Reguera, Vaz, M., Carrato, A., Monteagudo, R. Ferreiro

Get full text

Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience by Serrano, C. Saavedra, Puertas, P. Reguera, Saez, O. Martínez, Muñoz, F. Longo, García, A. Barquín, Artahona, V. Albarrán, Delgado, M. Villamayor, Cerrillo, J. Molina, de la Fuente, E. Corral, Huertas, R. Martín, Domingo, J. Serrano, Olmos, V. Pachón, Monteagudo, R. Ferreiro, Garrote, M. Rodriguez, Vaz, M., Fuentes, R., Guillén-Ponce, C., Carrato, A.

Get full text

Safety of self-expandable metal stents (SEMS) or emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab by Pacheco-Barcia, V., Solís, R. Mondéjar, Saez, O. Martínez, Muñoz, F. Longo, Bermejo, E., Monteagudo, J. Moreno, Marin, C., Correa, A., Maqueda, R., Rogado, J., de Paredes, A. Garcia, de Santiago, E. Rodriguez, Olmos, V. Pachón, Monteagudo, R. Ferreiro, Garrote, M. Rodriguez, Carrato, A., Donnay, O., Martin, E., Santander, C., Colomer, R.

Get full text

Analysis of classical high risk factors in stage III colon cancer: Experience at University Hospital Ramon y Cajal (UHRyC) by Domingo, J. Serrano, Huertas, R. Martín, García, A. Barquín, de la Fuente, E. Corral, Serrano, C. Saavedra, Delgado, M. Villamayor, Saez, O. Martínez, Muñoz, F. Longo, Olmos, V Pachón, Garrote, M. Rodriguez, Vaz, M., Puertas, P Reguera, Fuentes, R., Carrato, A., Monteagudo, R. Ferreiro

Get full text

Benefit of the addition of oxaliplatin to 5-FU/leucovorin or capecitabine in adjuvant therapy for stage II/III colorectal cancer in elderly patients: Experience in Ramon y Cajal University Hospital by de la Fuente, E. Corral, Serrano, C. Saavedra, Delgado, M. Villamayor, García, A. Barquín, Huertas, R. Martín, Domingo, J. Serrano, Saez, O. Martínez, Olmos, V. Pachón, Garrote, M. Rodriguez, Muñoz, F. Longo, Puertas, P. Reguera, Guillén-Ponce, C., Carrato, A., Monteagudo, R. Ferreiro

Get full text

793P - Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F., Jorge Fernandez, M., Yaya Tur, R., Diaz, S., Ortega, M., Dilla, T., Molero, A., Cervera, J.M.

“…Ramucirumab (RAM), as a single agent, or combined with paclitaxel, is indicated for the treatment of patients with advanced gastric cancer (AGC) or…”
Get full text

793PRamucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F, Jorge Fernandez, M, Yaya Tur, R, Diaz, S, Ortega, M, Dilla, T, Molero, A, Cervera, J M

“…Abstract Background Ramucirumab (RAM), as a single agent, or combined with paclitaxel, is indicated for the treatment of patients with advanced gastric cancer…”
Get full text

Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F., Jorge Fernandez, M., Yaya Tur, R., Diaz, S., Ortega, M., Dilla, T., Molero, A., Cervera, J.M.

Get full text

561P - Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) by Pacheco-Barcia, V.E., Mondejar, R., Martinez-Saez, O., Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J., Donnay, O., Santander, C., Mena, A Carrato, Bosch, R Colomer

“…Malignant bowel obstruction can occur in 18% of cases. SEMS can be an alternative to surgery. BV has been associated with bowel perforation but data on the…”
Get full text